Study of Different Local Treatments of Post COVID-19 Smell Dysfunction | ||
Iranian Journal of Otorhinolaryngology | ||
مقاله 2، دوره 34، شماره 6، بهمن و اسفند 2022، صفحه 281-288 اصل مقاله (1.06 M) | ||
نوع مقاله: Original | ||
شناسه دیجیتال (DOI): 10.22038/ijorl.2022.58339.3012 | ||
نویسندگان | ||
Soad A. Mohamad1؛ Ahmed M. Badwy2؛ Ramy M. El-Sabaa3؛ Hosam M. Ahmad4؛ Asmaa S. Mohamed* 5 | ||
1Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Deraya University, Minia, Egypt. | ||
2Department of Otorhinolaryngology, Faculty of Medicine, Minia University, Minia, Egypt. | ||
3Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia and Deraya Universities, Egypt. | ||
4Departments of Internal Medicine and Biomedical Chemistry, Egypt Ministry of Health and population, Minia, Egypt. | ||
5Department of Clinical Pharmacy, Faculty of Pharmacy, Port Said University, Port said, Egypt. | ||
چکیده | ||
Introduction: This study was designed to differentiate between the impact of the topical nasal spray of corticosteroids, antihistamines, a combination of them, and normal 0.2% saline in treating patients with post-coronavirus disease 2019 (COVID-19) smell dysfunction. Materials and Methods: Patients with hyposmia or anosmia (n = 240), who recently recovered from COVID-19, were enrolled in this trial and were randomly assigned to four parallel groups. Group I (G1) received a combination of topical corticosteroid and antihistamine nasal spray (n = 60). Group II (G2) received topical corticosteroid nasal spray (n = 60). Group III (G3) received antihistamine nasal spray (n = 60). Group IV (G4) received 0.2% normal nasal saline nasal spray (n = 60). The treatments were used in all groups for 3 weeks. The sense of smell was assessed using the butanol threshold and discrimination tests. The smell tests were evaluated weekly for 3 weeks. Results: The mean age of the patients was 51.9 ± 7.1 years; moreover, 83.8% and 16.3% were male and female, respectively. The results of the smell tests in the first week significantly improved with those in the third week (P< 0.001). The greatest degree of improvement was found in the first group, followed by the second, third, and fourth groups. Conclusions: The results suggest the ability of combination therapy of corticosteroid and antihistamine nasal spray to manage post-COVID-19 hyposmia or anosmia; however, this combination therapy was not superior to corticosteroid nasal spray. Trial registration ID: UMIN000043537 | ||
کلیدواژهها | ||
Antihistamines؛ Butanol threshold test؛ Corticosteroids؛ Discrimination test؛ Smell dysfunction؛ Post COVID-19 | ||
مراجع | ||
| ||
آمار تعداد مشاهده مقاله: 367 تعداد دریافت فایل اصل مقاله: 355 |